Nimotuzumab (TheraCIM, Theraloc)
Immunotherapy
Description
Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) for treatment of metastatic colorectal cancer. This targeted therapy is designed to block EGFR signaling pathways that promote tumor growth and metastasis. Nimotuzumab has been evaluated in combination with chemotherapy agents like trifluridine/tipiracil and irinotecan for patients with refractory metastatic colorectal cancer.
Mechanism of Action
Nimotuzumab binds specifically to the extracellular domain of EGFR, preventing the receptor from binding to its natural ligands including epidermal growth factor and transforming growth factor-alpha. By blocking EGFR activation, the antibody inhibits downstream signaling cascades including the RAS/RAF/MEK/ERK and PI3K/AKT pathways that regulate cell proliferation, survival, and angiogenesis in colorectal tumors.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | TheraCIM, Theraloc |
| Category | Immunotherapy |
 Status | Experimental |
 EMA Status | Not submitted to EMA |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.